Every trade that managers of ANN disclose to ASX is tracked on this page. The company sits in the Health Care sector. In the past year (18 October 2025 to 18 October 2026), 2 filings came from 2 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Compared with its exchange (2,530 companies, median 3 filings), a count of 2 filings is below the norm.
Insider buying of ANN has been absent for the past year.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2026 · cache
2 of 2 declarations
ANN is a company operating in the healthcare and pharmaceutical sector, listed on the XASX.
Purchases our model currently ranks for the recommendations list.
All recommendations